Allison Luo

1.5k total citations
30 papers, 1.0k citations indexed

About

Allison Luo is a scholar working on Genetics, Epidemiology and Immunology. According to data from OpenAlex, Allison Luo has authored 30 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Genetics, 14 papers in Epidemiology and 8 papers in Immunology. Recurrent topics in Allison Luo's work include Inflammatory Bowel Disease (19 papers), Microscopic Colitis (11 papers) and Immunodeficiency and Autoimmune Disorders (7 papers). Allison Luo is often cited by papers focused on Inflammatory Bowel Disease (19 papers), Microscopic Colitis (11 papers) and Immunodeficiency and Autoimmune Disorders (7 papers). Allison Luo collaborates with scholars based in United States, Canada and Belgium. Allison Luo's co-authors include Alan Kivitz, Jeffrey Kaine, C. Birbara, William J. Sandborn, Sheila Gujrathi, Richard Aranda, Xiaolu Tao, Michael Yellin, Bruce E. Sands and Paul Rutgeerts and has published in prestigious journals such as New England Journal of Medicine, Gastroenterology and Gut.

In The Last Decade

Allison Luo

28 papers receiving 1.0k citations

Peers

Countries citing papers authored by Allison Luo

Since Specialization

Citations

This map shows the geographic impact of Allison Luo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Allison Luo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Allison Luo more than expected).

Fields of papers citing papers by Allison Luo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Allison Luo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Allison Luo. The network helps show where Allison Luo may publish in the future.

Co-authorship network of co-authors of Allison Luo

This figure shows the co-authorship network connecting the top 25 collaborators of Allison Luo. A scholar is included among the top collaborators of Allison Luo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Allison Luo. Allison Luo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Impact of hospital readmission site on outcomes in acute ischemic stroke patients undergoing mechanical thrombectomy: a nationwide analysis 2025 ·Journal of NeuroInterventional Surgery ·Moxin Wu, Liqi Shu, M E Mawad, Thanh N. Nguyen, James E. Siegler, Allison Luo, Xiaofan Guo, (unknown), Han Xiao, Karen L. Furie, Shadi Yaghi	1
2	Su1774 RELATIONSHIP BETWEEN SYMPTOM RESOLUTION AND CLINICAL RESPONSES AFTER 12 WEEKS OF TREATMENT WITH TULISOKIBART IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: A POST HOC ANALYSIS FROM ARTEMIS-UC 2024 ·Gastroenterology ·(unknown), Brigid S. Boland, Rupert W. Leong, M. Horyński, (unknown), (unknown), Allison Luo	0
3	Su1772 EARLY CHANGE IN CDAI PREDICTS IMPROVED QUALITY OF LIFE AFTER 12-WEEK INDUCTION THERAPY WITH TULISOKIBART IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: A POST HOC ANALYSIS FROM APOLLO-CD 2024 ·Gastroenterology ·(unknown), (unknown), (unknown), (unknown), Allison Luo, (unknown)	1
4	Management of a fractured microcatheter during middle meningeal artery embolization 2024 ·Journal of NeuroInterventional Surgery ·(unknown), Allison Luo, Fadi Al Saiegh, Lee Birnbaum, Cristian Gragnaniello, Justin Mascitelli	0
5	Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis 2024 ·New England Journal of Medicine ·Bruce E. Sands, Brian G. Feagan, Laurent Peyrin‐Biroulet, Silvio Danese, David T. Rubin, Olivier Laurent, Allison Luo, Deanna D. Nguyen, Jiandong Lu, (unknown), Jarosław Leszczyszyn, Radosław Kempiński, Dermot McGovern, Christopher Ma, Timothy E. Ritter, Stephan Targan	23
6	DOP87 The Anti-TL1A Antibody PRA023 Demonstrated Proof-of-Concept in Crohn’s Disease: Phase 2a APOLLO-CD Study Results 2023 ·Journal of Crohn s and Colitis ·B G Feagan, B E Sands, Corey A. Siegel, Marla C. Dubinsky, (unknown), (unknown), (unknown), Allison Luo, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	22
7	477a A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PRA023 AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: ARTEMISUC, COHORT 1 2023 ·Gastroenterology ·Bruce E. Sands, Laurent Peyrin‐Biroulet, Silvio Danese, David T. Rubin, Séverine Vermeire, Christopher Ma, Timothy E. Ritter, Remo Panaccione, Brian G. Feagan, Dermot McGovern, Olivier Laurent, Allison Luo, Deanna D. Nguyen, (unknown), Anna Wiechowska–Kozłowska, Jarosław Leszczyszyn, Radosław Kempiński, Jarosław Kierkuś, Stephan R. Targan	1
8	OP40 PRA023 Demonstrated Efficacy and Favorable Safety as Induction Therapy for Moderately to Severely Active UC: Phase 2 ARTEMIS-UC Study Results 2023 ·Journal of Crohn s and Colitis ·Bruce E. Sands, Laurent Peyrin‐Biroulet, Silvio Danese, David T. Rubin, Séverine Vermeire, (unknown), Allison Luo, (unknown), (unknown), (unknown), (unknown), Radosław Kempiński, Jarosław Kierkuś, Christopher Ma, (unknown), B G Feagan, Ş. Targan	21
9	Tu1852 PHARMACOKINETICS AND PHARMACODYNAMICS OF OPL-002, A HIGHLY SELECTIVE S1P1R MODULATOR, IN HEALTHY ADULT VOLUNTEERS. 2020 ·Gastroenterology ·Allison Luo, Robert S. Lester, Robert M. Schwab, Kathleen M. Ogilvie, (unknown), Raju Mohan, John M. Nuss, William J. Sandborn	3
10	Use of the Endoscopic Healing Index for Monitoring of Disease Activity in Patients With Crohn’s Disease in the COVID Era 2020 ·Crohn s & Colitis 360 ·María T. Abreu, Lauren Okada, Thierry Dervieux, Allison Luo, Anjali Jain, Timothy E. Ritter, Stephen B. Hanauer	2
11	Eldelumab [anti-interferon-γ-inducible protein-10 antibody] Induction Therapy for Active Crohn’s Disease: a Randomised, Double-blind, Placebo-controlled Phase IIa Study 2017 ·Journal of Crohn s and Colitis ·William J. Sandborn, Paul Rutgeerts, Jean–Frédéric Colombel, Subrata Ghosh, Robert Petryka, Bruce E. Sands, P. P. Mitra, Allison Luo	27
12	Eldelumab [Anti-IP-10] Induction Therapy for Ulcerative Colitis: A Randomised, Placebo-Controlled, Phase 2b Study 2015 ·Journal of Crohn s and Colitis ·William J. Sandborn, Jean‐Frédéric Colombel, Subrata Ghosh, Bruce E. Sands, (unknown), Xavier Hébuterne, Rupert W. Leong, Brian Bressler, Thomas Ullman, Péter L. Lakatos, Walter Reinisch, (unknown), Allison Luo	53
13	Reliability among central readers in the evaluation of endoscopic findings from patients with Crohn's disease 2015 ·Gut ·Reena Khanna, Guangyong Zou, Geert D’Haens, Paul Rutgeerts, J.W.D. McDonald, Marco Daperno, Brian G. Feagan, William J. Sandborn, Elena Dubcenco, Larry Stitt, Margaret K. Vandervoort, Allan Donner, Allison Luo, Barrett G. Levesque	73
14	Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study 2013 ·Gut ·Lloyd Mayer, William J. Sandborn, (unknown), Karel Geboes, Robert Hardi, Michael Yellin, Xiaolu Tao, (unknown), Luisa Salter–Cid, Sheila Gujrathi, Richard Aranda, Allison Luo	119
15	SAT0001 Antibody Response to Pneumococcal and Influenza Vaccination in Patients With RA Receiving Subcutaneous Abatacept 2013 ·Annals of the Rheumatic Diseases ·Rieke Alten, Clifton O. Bingham, Stanley Cohen, Leonard H. Calabrese, Jeffrey R. Curtis, A. Jay Block, (unknown), S. Kelly, Allison Luo, (unknown), Mark C. Genovese	2
16	Safety of Abatacept Administered Intravenously in Treatment of Rheumatoid Arthritis: Integrated Analyses of up to 8 Years of Treatment from the Abatacept Clinical Trial Program 2013 ·The Journal of Rheumatology ·Michael E. Weinblatt, Larry W. Moreland, René Westhovens, Roger B. Cohen, Sheila Kelly, Nader Khan, R. Pappu, I. Delaet, Allison Luo, Sheila Gujrathi, Marc C. Hochberg	104
17	Abatacept for Crohn's Disease and Ulcerative Colitis 2012 ·Gastroenterology ·William J. Sandborn, Jean‐Frédéric Colombel, Bruce E. Sands, Paul Rutgeerts, Stephan R. Targan, Remo Panaccione, Brian Bressler, K. Geboes, Stefan Schreiber, Richard Aranda, Sheila Gujrathi, Allison Luo, Yun Peng, Luisa Salter–Cid, Stephen B. Hanauer	111
18	Abatacept in subjects who switch from intravenous to subcutaneous therapy: results from the phase IIIb ATTUNE study 2012 ·Annals of the Rheumatic Diseases ·Edward Keystone, Joel M. Kremer, Anthony S. Russell, J. Box, Carlos Abud‐Mendoza, Mario Alberto Garza‐Elizondo, Allison Luo, Richard Aranda, I. Delaet, René Swanink, Sheila Gujrathi, Michael E. Luggen	43
19	A phase II, randomized, double‐blind, placebo‐controlled study evaluating the efficacy and safety of MDX‐1100, a fully human anti‐CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis 2011 ·Arthritis & Rheumatism ·Michael Yellin, (unknown), Andra Bălănescu, (unknown), Vira Tseluyko, (unknown), Xiaolu Tao, Pina M. Cardarelli, Heidi Leblanc, Geoff Nichol, Codrina Ancuța, Rodica Chirieac, Allison Luo	149
20	A randomized, double‐blind, placebo‐controlled, phase III study of the human anti‐tumor necrosis factor antibody adalimumab administered as subcutaneous injections in Korean rheumatoid arthritis patients treated with methotrexate 2007 ·APLAR Journal of Rheumatology ·Ho‐Youn Kim, (unknown), Yeong Wook Song, Dae‐Hyun Yoo, (unknown), Bin Yoo, Allison Luo	60

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact